Page last updated: 2024-09-03

gefitinib and Dermatoses

gefitinib has been researched along with Dermatoses in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (63.64)29.6817
2010's3 (27.27)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Choi, CW; Kim, JY; Kim, KI; Lee, BJ; Lee, JH1
Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y1
Guo, Z; Li, J1
Chang, H; Cho, BC; Cho, J; Ha, SJ; Hong, YK; Jeong, JH; Kim, HR; Kim, JH; Kim, SH; Kim, SM; Shim, HS; Sung, JH; Tania, C1
Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H1
Bartolini, S; Calandri, C; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Lombardo, L; Spreafico, A; Tamberi, S; Toschi, L; Villa, E1
Bartolini, S; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Villa, E1
Han, JY; Hong, EK; Kim, HK; Kim, HY; Lee, DH; Lee, EK; Lee, HG; Lee, JJ; Lee, JS1
Kano, Y1
Burgin, S; Heidary, N; Naik, H1

Reviews

2 review(s) available for gefitinib and Dermatoses

ArticleYear
[Adverse drug reactions induced by molecular target therapy].
    Arerugi = [Allergy], 2007, Volume: 56, Issue:12

    Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Cetuximab; Communicable Diseases; ErbB Receptors; Etanercept; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Immunoglobulin G; Infliximab; Lung Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Tumor Necrosis Factor; Skin Diseases; Tumor Necrosis Factor-alpha

2007
Chemotherapeutic agents and the skin: An update.
    Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids

2008

Trials

5 trial(s) available for gefitinib and Dermatoses

ArticleYear
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 79, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Skin Diseases; Treatment Outcome

2013
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases

2002
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).
    British journal of cancer, 2004, Jan-12, Volume: 90, Issue:1

    Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases

2004
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Skin Diseases; Survival Analysis; Treatment Outcome

2004
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-15, Volume: 11, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin Diseases; Smoking; Survival Analysis; Treatment Outcome

2005

Other Studies

4 other study(ies) available for gefitinib and Dermatoses

ArticleYear
Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine: A case report.
    Medicine, 2021, Feb-05, Volume: 100, Issue:5

    Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Tapering; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Phytotherapy; Progression-Free Survival; Skin Diseases

2021
Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
    Prescrire international, 2009, Volume: 18, Issue:102

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diarrhea; Docetaxel; Drug Approval; ErbB Receptors; France; Gefitinib; Humans; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Quinazolines; Skin Diseases; Taxoids

2009
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure

2011
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome

2012